Medical Treatment ~ Ovarian Cancer
~ Genetics of Breast & Ovarian Cancer

Return to More Current References

Older References


    • FDA Approves First PARP Inhibitor with Myriad's BRACAnalysis as CDx in Advanced Ovarian Cancer.
    • Turna Ray.
    • GenomeWeb, 2014 Dec 23.
    • A phase II clinical trial of 6-mercaptopurine (6MP) and methotrexate in patients with BRCA defective tumours: a study protocol.
    • Nicum S, Roberts C, Boyle L, Kopijasz S, Gourley C, Hall M, Montes A, Poole C, Collins L, Schuh A, Dutton SJ; 6MP Collaborative Group.
    • BMC Cancer. 2014 Dec 19;14(1):983. doi: 10.1186/1471-2407-14-983.
    • FDA Approves Myriad's BRACAnalysis CDx for Use with Ovarian Cancer Drug.
    • GenomeWeb staff reporter.
    • GenomeWeb, 2014 Dec 19.
    • FDA Approves Olaparib (Lynparza) for BRCA Ovarian Cancer.
    • Zosia Chustecka.
    • Medscape Oncology, 2014 Dec 19.
    • Olaparib Approved in Europe for BRCA Ovarian Cancer.
    • Chustecka Z.
    • Medscape. 2014 Dec 18.
    • Association of BRCA1/2 defects with genomic scores predictive of DNA damage repair deficiency among breast cancer subtypes.
    • Timms KM, Abkevich V, Hughes E, Neff C, Reid J, Morris B, Kalva S, Potter J, Tran TV, Chen J, Iliev D, Sangale Z, Tikishvili E, Perry M, Zharkikh A, Gutin A, Lanchbury JS.
    • Breast Cancer Res. 2014 Dec 5;16(6):475. doi: 10.1186/s13058-014-0475-x.
    • A Genomic Instability Score in Discriminating Nonequivalent Outcomes of BRCA1/2 Mutations and in Predicting Outcomes of Ovarian Cancer Treated with Platinum-Based Chemotherapy.
    • Zhang S, Yuan Y, Hao D.
    • PLoS One. 2014 Dec 1;9(12):e113169. doi: 10.1371/journal.pone.0113169. eCollection 2014.
    • Myriad, AbbVie Expand Tumor BRACAnalysis CDx Collaboration.
    • [No author given]
    • Clinical OMICs. 1(14):5. 2014 Nov 19.
    • Cytoreduction surgery with hyperthermic intraperitoneal chemotherapy in recurrent ovarian cancer improves progression-free survival, especially in BRCA-positive patients- a case-control study.
    • Safra T, Grisaru D, Inbar M, Abu-Abeid S, Dayan D, Matceyevsky D, Weizman A, Klausner JM.
    • J Surg Oncol. 2014 Nov;110(6):661-5. doi: 10.1002/jso.23688. Epub 2014 Jun 24.
    • European OK for Olaparib in Ovarian Cancer.
    • Chustecka Z.
    • Medscape. 2014 Oct 24.
    • BRCA1/2 Mutation Status Is an Independent Factor of Improved Survival for Advanced (Stage III-IV) Ovarian Cancer.
    • Rudaitis V, Zvirblis T, Kanopiene D, Janulynaite D, Griskevicius L, Janavicius R.
    • Int J Gynecol Cancer. 2014 Oct;24(8):1395-400. doi: 10.1097/IGC.0000000000000247.
    • Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study.
    • Liu JF, Barry WT, Birrer M, Lee JM, Buckanovich RJ, Fleming GF, Rimel B, Buss MK, Nattam S, Hurteau J, Luo W, Quy P, Whalen C, Obermayer L, Lee H, Winer EP, Kohn EC, Ivy SP, Matulonis UA.
    • Lancet Oncol. 2014 Oct;15(11):1207-14. doi: 10.1016/S1470-2045(14)70391-2. Epub 2014 Sep 10.
    • Evidence for clinical efficacy of mitomycin C in heavily pretreated ovarian cancer patients carrying germ-line BRCA1 mutation.
    • Moiseyenko VM, Chubenko VA, Moiseyenko FV, Zhabina AS, Gorodnova TV, Komarov YI, Bogdanov AA, Sokolenko AP, Imyanitov EN.
    • Med Oncol. 2014 Oct;31(10):199. doi: 10.1007/s12032-014-0199-x. Epub 2014 Sep 4.
    • Maintenance therapy in ovarian cancer.
    • Khalique S, Hook JM, Ledermann JA.
    • Curr Opin Oncol. 2014 Sep;26(5):521-8. doi: 10.1097/CCO.0000000000000110.
    • Review
    • PARP inhibition and synthetic lethality in ovarian cancer.
    • Eskander RN, Tewari KS.
    • Expert Rev Clin Pharmacol. 2014 Sep;7(5):613-22. doi: 10.1586/17512433.2014.930662. Epub 2014 Jul 2.
    • Review
    • Evolution of pre-existing versus acquired resistance to platinum drugs and PARP inhibitors in BRCA-associated cancers.
    • Yamamoto KN, Hirota K, Takeda S, Haeno H.
    • PLoS One. 2014 Aug 26;9(8):e105724. doi: 10.1371/journal.pone.0105724. eCollection 2014.
    • Myriad Awaits BRACAnalysis CDx Approval as it Works to Move Hereditary Cancer Testing to MyRisk
    • Molika Ashford
    • GenomeWeb, 2014 Aug 13
    • News
    • Phase I study of olaparib in combination with liposomal doxorubicin in patients with advanced solid tumours.
    • Del Conte G, Sessa C, von Moos R, Viganò L, Digena T, Locatelli A, Gallerani E, Fasolo A, Tessari A, Cathomas R, Gianni L.
    • Br J Cancer. 2014 Aug 12;111(4):651-9. doi: 10.1038/bjc.2014.345. Epub 2014 Jul 15.
    • Phase I trial of olaparib in combination with cisplatin for the treatment of patients with advanced breast, ovarian and other solid tumors.
    • Balmaña J, Tung NM, Isakoff SJ, Graña B, Ryan PD, Saura C, Lowe ES, Frewer P, Winer E, Baselga J, Garber JE.
    • Ann Oncol. 2014 Aug;25(8):1656-63. doi: 10.1093/annonc/mdu187. Epub 2014 May 14.
    • An ex vivo assay of XRT-induced Rad51 foci formation predicts response to PARP-inhibition in ovarian cancer.
    • Shah MM, Dobbin ZC, Nowsheen S, Wielgos M, Katre AA, Alvarez RD, Konstantinopoulos PA, Yang ES, Landen CN.
    • Gynecol Oncol. 2014 Aug;134(2):331-7. doi: 10.1016/j.ygyno.2014.05.009. Epub 2014 May 15.
    • Made-to-measure medicine: BRCA and gynaecological cancer.
    • Foulkes WD.
    • Lancet Oncol. 2014 Jul;15(8):783-5. doi: 10.1016/S1470-2045(14)70246-3. Epub 2014 May 31.
    • Commentary
    • Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial.
    • Ledermann J, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, Scott CL, Meier W, Shapira-Frommer R, Safra T, Matei D, Fielding A, Spencer S, Dougherty B, Orr M, Hodgson D, Barrett JC, Matulonis U.
    • Lancet Oncol. 2014 Jul;15(8):852-61. doi: 10.1016/S1470-2045(14)70228-1. Epub 2014 May 31.
    • FDA Panel Votes Against Accelerated Approval for Olaparib.
    • Hand L.
    • Medscape. 2014 Jun 26.
    • Genomic scars as biomarkers of homologous recombination deficiency and drug response in breast and ovarian cancers.
    • Watkins JA, Irshad S, Grigoriadis A, Tutt AN.
    • Breast Cancer Res. 2014 Jun 3;16(3):211. doi: 10.1186/bcr3670.
    • Targeted Drug Combo Improves Outcomes in Ovarian Cancer.
    • Nelson R.
    • Medscape. 2014 Jun 1.
    • The immunomodulatory effects of pegylated liposomal doxorubicin are amplified in BRCA1- deficient ovarian tumors and can be exploited to improve treatment response in a mouse model.
    • Mantia-Smaldone G, Ronner L, Blair A, Gamerman V, Morse C, Orsulic S, Rubin S, Gimotty P, Adams S.
    • Gynecol Oncol. 2014 Jun;133(3):584-590. doi: 10.1016/j.ygyno.2014.03.565. Epub 2014 Mar 27.
    • Checkpoint kinase 2 (Chk2) supports sensitivity to platinum-based treatment in high grade serous ovarian cancer.
    • Alkema NG, Tomar T, van der Zee AG, Everts M, Meersma GJ, Hollema H, de Jong S, van Vugt MA, Wisman GB.
    • Gynecol Oncol. 2014 Jun;133(3):591-8. doi: 10.1016/j.ygyno.2014.03.557. Epub 2014 Mar 20.
    • Suberoylanilide hydroxamic acid (SAHA) enhances olaparib activity by targeting homologous recombination DNA repair in ovarian cancer.
    • Konstantinopoulos PA, Wilson AJ, Saskowski J, Wass E, Khabele D.
    • Gynecol Oncol. 2014 Jun;133(3):599-606. doi: 10.1016/j.ygyno.2014.03.007. Epub 2014 Mar 11.
    • Phosphorylation of ribosomal protein S6 confers PARP inhibitor resistance in BRCA1-deficient cancers.
    • Sun CK, Zhang F, Xiang T, Chen Q, Pandita TK, Huang Y, Hu MC, Yang Q.
    • Oncotarget. 2014 May 30;5(10):3375-85.
    • Phase I/Ib Study of Olaparib and Carboplatin in BRCA1 or BRCA2 Mutation-Associated Breast or Ovarian Cancer With Biomarker Analyses.
    • Lee JM, Hays JL, Annunziata CM, Noonan AM, Minasian L, Zujewski JA, Yu M, Gordon N, Ji J, Sissung TM, Figg WD, Azad N, Wood BJ, Doroshow J, Kohn EC.
    • J Natl Cancer Inst. 2014 May 19;106(6). pii: dju089. doi: 10.1093/jnci/dju089. Print 2014 Jun.
    • On the road to PARPi-platin.
    • Bookman MA.
    • J Natl Cancer Inst. 2014 May 19;106(6):dju119. doi: 10.1093/jnci/dju119. Print 2014 Jun.
    • What Does BRCA Have to Do With It? PARP Inhibitors in Ovarian Cancer.
    • Thomas Herzog, Elizabeth M. Swisher, Kristin K. Zorn.
    • Medscape Education Oncology, 2014 May 6.
    • [On the prospects of using the DNA repair inhibitors in radiotherapy of tumors].
    • Gaziev AI.
    • Radiats Biol Radioecol. 2014 May-Jun;54(3):229-40.
    • [Article in Russian]
    • Ovarian cancer in BRCA mutation carriers: improved outcome after intraperitoneal (IP) cisplatin.
    • Kwa M, Edwards S, Downey A, Reich E, Wallach R, Curtin J, Muggia F.
    • Ann Surg Oncol. 2014 May;21(5):1468-73. doi: 10.1245/s10434-013-3277-y. Epub 2013 Oct 1.
    • PARP inhibitors in ovarian cancer: Current status and future promise.
    • Liu JF, Konstantinopoulos PA, Matulonis UA.
    • Gynecol Oncol. 2014 May;133(2):362-369. doi: 10.1016/j.ygyno.2014.02.039. Epub 2014 Mar 4.
    • Review
    • Ovarian cancer-associated mutations disable catalytic activity of CDK12, a kinase that promotes homologous recombination repair and resistance to cisplatin and poly(ADP-ribose) polymerase inhibitors.
    • Joshi PM, Sutor SL, Huntoon CJ, Karnitz LM.
    • J Biol Chem. 2014 Mar 28;289(13):9247-53. doi: 10.1074/jbc.M114.551143. Epub 2014 Feb 19.
    • Veliparib Active in BRCA-Positive Ovarian Cancer.
    • Fran Lowry.
    • Medscape Medical News from the Society of Gynecologic Oncology (SGO) 45th Annual Meeting on Women's Cancer, 2014 Mar 26.
    • Reversing Platinum Resistance in High-Grade Serous Ovarian Carcinoma: Targeting BRCA and the Homologous Recombination System.
    • Wiedemeyer WR, Beach JA, Karlan BY.
    • Front Oncol. 2014 Mar 3;4:34. doi: 10.3389/fonc.2014.00034. eCollection 2014.
    • Triapine disrupts CtIP-mediated homologous recombination repair and sensitizes ovarian cancer cells to PARP and topoisomerase inhibitors.
    • Lin ZP, Ratner ES, Whicker ME, Lee Y, Sartorelli AC.
    • Mol Cancer Res. 2014 Mar;12(3):381-93. doi: 10.1158/1541-7786.MCR-13-0480. Epub 2014 Jan 10.
    • Beyond Breast and Ovarian Cancers: PARP Inhibitors for BRCA Mutation-Associated and BRCA-Like Solid Tumors.
    • O'Sullivan CC, Moon DH, Kohn EC, Lee JM.
    • Front Oncol. 2014 Feb 28;4:42. eCollection 2014.
    • BRCA 1/2-Mutation Related and Sporadic Breast and Ovarian Cancers: More Alike than Different.
    • Burgess M, Puhalla S.
    • Front Oncol. 2014 Feb 27;4:19. eCollection 2014.
    • Molecular Pathways: How Can BRCA-Mutated Tumors Become Resistant to PARP Inhibitors?
    • Bouwman P, Jonkers J.
    • Clin Cancer Res. 2014 Feb 1;20(3):540-7. doi: 10.1158/1078-0432.CCR-13-0225. Epub 2013 Nov 22.
    • Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas.
    • Pennington KP, Walsh T, Harrell MI, Lee MK, Pennil CC, Rendi MH, Thornton A, Norquist BM, Casadei S, Nord AS, Agnew KJ, Pritchard CC, Scroggins S, Garcia RL, King MC, Swisher EM.
    • Clin Cancer Res. 2014 Feb 1;20(3):764-75. doi: 10.1158/1078-0432.CCR-13-2287. Epub 2013 Nov 15.

    Related:

    Comments on NSGC Discussion Forum Cancer SIG

    Subject: PALB2 and Ovarian Cancer

    Comment, Letter

    DNA repair mutations and outcomes in ovarian cancer--letter.

    Reply, Letter

    DNA repair mutations and outcomes in ovarian cancer--response.

    • 'BRCAness' and its implications for platinum action in gynecologic cancer.
    • Muggia F, Safra T.
    • Anticancer Res. 2014 Feb;34(2):551-6.
    • PARP inhibitors for anticancer therapy.
    • Curtin N.
    • Biochem Soc Trans. 2014 Feb;42(1):82-8. doi: 10.1042/BST20130187.
    • [Hereditary ovarian carcinomas: clinico-biological features and treatment].
    • Floquet A, Stoeckle E, Croce S, Longy M, Mc Grogan G, Barouk E, Bubien V, Garbay D, Joly E, Guyon F.
    • Bull Cancer. 2014 Feb;101(2):167-74. doi: 10.1684/bdc.2014.1888.
    • Review, [Article in French]
    • Natural and glucosyl flavonoids inhibit poly(ADP-ribose) polymerase activity and induce synthetic lethality in BRCA mutant cells.
    • Maeda J, Roybal EJ, Brents CA, Uesaka M, Aizawa Y, Kato TA.
    • Oncol Rep. 2014 Feb;31(2):551-6. doi: 10.3892/or.2013.2902. Epub 2013 Dec 5.
    • Poly (ADP-ribose) polymerase 1 transcriptional regulation: a novel crosstalk between histone modification H3K9ac and ETS1 motif hypomethylation in BRCA1-mutated ovarian cancer.
    • Li D, Bi FF, Cao JM, Cao C, Li CY, Liu B, Yang Q.
    • Oncotarget. 2014 Jan 15;5(1):291-7.
    • Genome-wide Profiling of Genetic Synthetic Lethality Identifies CDK12 as a Novel Determinant of PARP1/2 Inhibitor Sensitivity.
    • Bajrami I, Frankum JR, Konde A, Miller RE, Rehman FL, Brough R, Campbell J, Sims D, Rafiq R, Hooper S, Chen L, Kozarewa I, Assiotis I, Fenwick K, Natrajan R, Lord CJ, Ashworth A.
    • Cancer Res. 2014 Jan 1;74(1):287-97. doi: 10.1158/0008-5472.CAN-13-2541. Epub 2013 Nov 15.
    • PARP Inhibitors for BRCA1/2 mutation-associated and BRCA-like malignancies.
    • Lee JM, Ledermann JA, Kohn EC.
    • Ann Oncol. 2014 Jan;25(1):32-40. doi: 10.1093/annonc/mdt384. Epub 2013 Nov 12.
    • BRCA1 and BRCA2 - update and implications on the genetics of breast cancer: a clinical perspective.
    • Foulkes W.
    • Clin Genet. 2014 Jan;85(1):1-4. doi: 10.1111/cge.12291. Epub 2013 Oct 25.
    • Editorial / Commentary
    • Targeting the BRCA1/2 Tumor Suppressors.
    • Rosen EM, Pishvaian MJ.
    • Curr Drug Targets. 2014 Jan;15(1):17-31.
    • Review
    • Clinical implications of using molecular diagnostics for ovarian cancers.
    • Kohn EC, Romano S, Lee JM.
    • Ann Oncol. 2013 Dec;24 Suppl 10:x22-26. doi: 10.1093/annonc/mdt464.
    • Therapeutic applications of PARP inhibitors: anticancer therapy and beyond.
    • Curtin NJ, Szabo C.
    • Mol Aspects Med. 2013 Dec;34(6):1217-56. doi: 10.1016/j.mam.2013.01.006. Epub 2013 Jan 29.
    • Appraising iniparib, the PARP inhibitor that never was--what must we learn?
    • Mateo J, Ong M, Tan DS, Gonzalez MA, de Bono JS.
    • Nat Rev Clin Oncol. 2013 Dec;10(12):688-96. doi: 10.1038/nrclinonc.2013.177. Epub 2013 Oct 15.
    • Review
    • Synthetic lethality between CCNE1 amplification and loss of BRCA1.
    • Etemadmoghadam D, Weir BA, Au-Yeung G, Alsop K, Mitchell G, George J; Australian Ovarian Cancer Study Group, Davis S, D'Andrea AD, Simpson K, Hahn WC, Bowtell DD.
    • Proc Natl Acad Sci U S A. 2013 Nov 26;110(48):19489-94. doi: 10.1073/pnas.1314302110. Epub 2013 Nov 11.
    • miR-9 Regulation of BRCA1 and Ovarian Cancer Sensitivity to Cisplatin and PARP Inhibition.
    • Sun C, Li N, Yang Z, Zhou B, He Y, Weng D, Fang Y, Wu P, Chen P, Yang X, Ma D, Zhou J, Chen G.
    • J Natl Cancer Inst. 2013 Nov 20;105(22):1750-8. doi: 10.1093/jnci/djt302. Epub 2013 Oct 29.
    • PARP Inhibitors in Cancer Therapy: Magic Bullets but Moving Targets.
    • Shah GM, Robu M, Purohit NK, Rajawat J, Tentori L, Graziani G.
    • Front Oncol. 2013 Nov 14;3:279. doi: 10.3389/fonc.2013.00279. eCollection 2013.
    • Tumor mutation burden forecasts outcome in ovarian cancer with BRCA1 or BRCA2 mutations.
    • Birkbak NJ, Kochupurakkal B, Izarzugaza JM, Eklund AC, Li Y, Liu J, Szallasi Z, Matulonis UA, Richardson AL, Iglehart JD, Wang ZC.
    • PLoS One. 2013 Nov 12;8(11):e80023. doi: 10.1371/journal.pone.0080023. eCollection 2013.
    • BRCA1- and BRCA2-related mutations: therapeutic implications in ovarian cancer.
    • Pothuri B.
    • Ann Oncol. 2013 Nov;24 Suppl 8:viii22-viii27. doi: 10.1093/annonc/mdt307.
    • Mechanisms of resistance to therapies targeting BRCA-mutant cancers.
    • Lord CJ, Ashworth A.
    • Nat Med. 2013 Nov;19(11):1381-8. doi: 10.1038/nm.3369. Epub 2013 Oct 7.
    • Review
    • Stabilization of mutant BRCA1 protein confers PARP inhibitor and platinum resistance.
    • Johnson N, Johnson SF, Yao W, Li YC, Choi YE, Bernhardy AJ, Wang Y, Capelletti M, Sarosiek KA, Moreau LA, Chowdhury D, Wickramanayake A, Harrell MI, Liu JF, D'Andrea AD, Miron A, Swisher EM, Shapiro GI.
    • Proc Natl Acad Sci U S A. 2013 Oct 15;110(42):17041-17046. Epub 2013 Oct 1.
    • Efficacy of chemotherapy in BRCA1/2 mutation carrier ovarian cancer in the setting of PARP inhibitor resistance: a multi-institutional study.
    • Ang JE, Gourley C, Powell CB, High H, Shapira-Frommer R, Castonguay V, De Greve J, Atkinson T, Yap TA, Sandhu S, Banerjee S, Chen LM, Friedlander ML, Kaufman B, Oza AM, Matulonis U, Barber LJ, Kozarewa I, Fenwick K, Assiotis I, Campbell J, Chen L, de Bono JS, Gore ME, Lord CJ, Ashworth A, Kaye SB.
    • Clin Cancer Res. 2013 Oct 1;19(19):5485-93. doi: 10.1158/1078-0432.CCR-13-1262. Epub 2013 Aug 6.
    • The Role of PARP Inhibitors in the Treatment of Gynecologic Malignancies.
    • Reinbolt RE, Hays JL.
    • Front Oncol. 2013 Oct 1;3:237. doi: 10.3389/fonc.2013.00237.
    • Emerging treatment options for recurrent ovarian cancer: the potential role of olaparib.
    • Shaw HM, Hall M.
    • Onco Targets Ther. 2013 Sep 3;6:1197-206. doi: 10.2147/OTT.S30748.
    • A Phase 1 trial of the poly(ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancer.
    • Liu JF, Tolaney SM, Birrer M, Fleming GF, Buss MK, Dahlberg SE, Lee H, Whalen C, Tyburski K, Winer E, Ivy P, Matulonis UA.
    • Eur J Cancer. 2013 Sep;49(14):2972-8. doi: 10.1016/j.ejca.2013.05.020. Epub 2013 Jun 27.
    • Deleterious BRCA1/2 mutation is an independent risk factor for carboplatin hypersensitivity reactions.
    • Moon DH, Lee JM, Noonan AM, Annunziata CM, Minasian L, Houston N, Hays JL, Kohn EC.
    • Br J Cancer. 2013 Aug 20;109(4):1072-8. doi: 10.1038/bjc.2013.389. Epub 2013 Jul 18.
    • Olaparib: a promising PARP inhibitor in ovarian cancer therapy.
    • Chen Y, Zhang L, Hao Q.
    • Arch Gynecol Obstet. 2013 Aug;288(2):367-74. doi: 10.1007/s00404-013-2856-2. Epub 2013 Apr 26.
    • Review
    • Poly(adenosine diphosphate-ribose) polymerase expression in BRCA-proficient ovarian high-grade serous carcinoma; association with patient survival.
    • Gan A, Green AR, Nolan CC, Martin S, Deen S.
    • Hum Pathol. 2013 Aug;44(8):1638-47. doi: 10.1016/j.humpath.2013.01.015. Epub 2013 Apr 8.
    • The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial.
    • Sandhu SK, Schelman WR, Wilding G, Moreno V, Baird RD, Miranda S, Hylands L, Riisnaes R, Forster M, Omlin A, Kreischer N, Thway K, Gevensleben H, Sun L, Loughney J, Chatterjee M, Toniatti C, Carpenter CL, Iannone R, Kaye SB, de Bono JS, Wenham RM.
    • Lancet Oncol. 2013 Aug;14(9):882-92. doi: 10.1016/S1470-2045(13)70240-7. Epub 2013 Jun 28.

    Related:

    Commentary:

    PARP inhibitors: pitfalls and promises.

    • Inhibition of DNA damage repair by artificial activation of PARP with siDNA.
    • Croset A, Cordelières FP, Berthault N, Buhler C, Sun JS, Quanz M, Dutreix M.
    • Nucleic Acids Res. 2013 Aug;41(15):7344-55. doi: 10.1093/nar/gkt522. Epub 2013 Jun 12.
    • RAD52 inactivation is synthetically lethal with deficiencies in BRCA1 and PALB2 in addition to BRCA2 through RAD51-mediated homologous recombination.
    • Lok BH, Carley AC, Tchang B, Powell SN.
    • Oncogene. 2013 Jul 25;32(30):3552-8. doi: 10.1038/onc.2012.391. Epub 2012 Sep 10.
    • Olaparib shows promise in multiple tumor types.
    • [No authors listed]
    • Cancer Discov. 2013 Jul;3(7):OF5. doi: 10.1158/2159-8290.CD-NB2013-082. Epub 2013 Jun 6.
    • Unmet needs in ovarian cancer: dividing histologic subtypes to exploit novel targets and pathways.
    • Galic V, Coleman RL, Herzog TJ.
    • Curr Cancer Drug Targets. 2013 Jul;13(6):698-707.
    • Phase I/Ib study of the PARP inhibitor (PARPi) olaparib (O/AZD2281) in combination with carboplatin (C) in ovarian cancer (OvCa) patients with BRCA1/2 mutations (OvCaMUT +) and high grade serous OvCa (HGSOC) with low genetic risk (NCT00647062).
    • Lee J, Hays J, Noonan A, Annunziata C, Minasian L, Zujewski J, Houston N, Hearn J, Yu M, Kohn E.
    • Gynecologic Oncology. 2013 Jul;130(1):e11. 44th Annual Meeting of the Society of Gynecologic Oncology. doi: 10.1016/j.ygyno.2013.04.083.
    • Conference abstract
    • PARP Inhibitor Research Update.
    • Susan Domchek.
    • FORCE. Be Empowered Webinars. 2013 Jun 27.
    • BRCA1 reversion mutation acquired after treatment identified by liquid biopsy.
    • Mayor P, Gay LM, Lele S, Elvin JA.
    • Gynecol Oncol Rep. 2017 Jun 21;21:57-60. doi: 10.1016/j.gore.2017.06.010. eCollection 2017 Aug.
    • ATR Inhibition Broadly Sensitizes Ovarian Cancer Cells to Chemotherapy Independent of BRCA Status.
    • Huntoon CJ, Flatten KS, Wahner Hendrickson AE, Huehls AM, Sutor SL, Kaufmann SH, Karnitz LM.
    • Cancer Res. 2013 Jun 15;73(12):3683-91. doi: 10.1158/0008-5472.CAN-13-0110. Epub 2013 Apr 2.
    • Cost-effectiveness of BRCA1 and BRCA2 mutation testing to target PARP inhibitor use in platinum-sensitive recurrent ovarian cancer.
    • Secord AA, Barnett JC, Ledermann JA, Peterson BL, Myers ER, Havrilesky LJ.
    • Int J Gynecol Cancer. 2013 Jun;23(5):846-52. doi: 10.1097/IGC.0b013e31829527bd.
    • Therapeutic potential of the poly(ADP-ribose) polymerase inhibitor rucaparib for the treatment of sporadic human ovarian cancer.
    • Ihnen M, zu Eulenburg C, Kolarova T, Qi JW, Manivong K, Chalukya M, Dering J, Anderson L, Ginther C, Meuter A, Winterhoff B, Jones S, Velculescu VE, Venkatesan N, Rong HM, Dandekar S, Udar N, Jänicke F, Los G, Slamon DJ, Konecny GE.
    • Mol Cancer Ther. 2013 Jun;12(6):1002-15. doi: 10.1158/1535-7163.MCT-12-0813. Epub 2013 May 31.
    • BRCA1/2 mutation analysis in 41 ovarian cell lines reveals only one functionally deleterious BRCA1 mutation.
    • Stordal B, Timms K, Farrelly A, Gallagher D, Busschots S, Renaud M, Thery J, Williams D, Potter J, Tran T, Korpanty G, Cremona M, Carey M, Li J, Li Y, Aslan O, O'Leary JJ, Mills GB, Hennessy BT.
    • Mol Oncol. 2013 Jun;7(3):567-79. doi: 10.1016/j.molonc.2012.12.007. Epub 2013 Jan 31.
    • BRCA1 expression and improved survival in ovarian cancer patients treated with intraperitoneal cisplatin and paclitaxel: a Gynecologic Oncology Group Study.
    • Lesnock JL, Darcy KM, Tian C, Deloia JA, Thrall MM, Zahn C, Armstrong DK, Birrer MJ, Krivak TC.
    • Br J Cancer. 2013 Apr 2;108(6):1231-7. doi: 10.1038/bjc.2013.70. Epub 2013 Mar 5.

    Related:

    Research news: Can BRCA Expression Predict Response to Chemotherapy? (Medscape)

    • Implications of BRCA1 and BRCA2 mutations for the efficacy of paclitaxel monotherapy in advanced ovarian cancer.
    • Tan DS, Yap TA, Hutka M, Roxburgh P, Ang J, Banerjee S, Grzybowska E, Gourley C, Gore ME, Kaye SB.
    • Eur J Cancer. 2013 Apr;49(6):1246-53. doi: 10.1016/j.ejca.2012.11.016. Epub 2012 Dec 19.
    • Promoter hypomethylation, especially around the E26 transformation-specific motif, and increased expression of poly (ADP-ribose) polymerase 1 in BRCA-mutated serous ovarian cancer.
    • Bi FF, Li D, Yang Q.
    • BMC Cancer. 2013 Feb 26;13:90. doi: 10.1186/1471-2407-13-90.
    • Genetics of Susceptibility to Sporadic Ovarian Cancer.
    • Katabathina VS, Prasad SR.
    • eLS. John Wiley & Sons Ltd, Chichester. http://www.els.net. doi: 10.1002/9780470015902.a0023853. 2013 Feb.
    • Prolonged response of relapsed high grade serous ovarian carcinoma to the oral angiokinase inhibitor nintedanib in a patient with a germline BRCA1 mutation.
    • Wong HH, Parkinson C, Ledermann JA, Brenton JD, Merger M, Shaw A, Patterson A, Shafi M, Earl HM.
    • Gynecol Oncol Case Rep. 2013 Jan 1;3:7-10. doi: 10.1016/j.gynor.2012.10.003.
    • Major clinical research advances in gynecologic cancer in 2012.
    • Suh DH, Kim JW, Kim K, Kim HJ, Lee KH.
    • J Gynecol Oncol. 2013 Jan;24(1):66-82. doi: 10.3802/jgo.2013.24.1.66. Epub 2013 Jan 8.
    • Palliative systemic therapy for women with recurrent epithelial ovarian cancer: current options.
    • Elit L, Hirte H.
    • Onco Targets Ther. 2013;6:107-18. doi: 10.2147/OTT.S30238. Epub 2013 Feb 26.
    • Mitochondrial DNA mutation in serous ovarian cancer: implications for mitochondria-coded genes in chemoresistance.
    • Guerra F, Perrone AM, Kurelac I, Santini D, Ceccarelli C, Cricca M, Zamagni C, De Iaco P, Gasparre G.
    • J Clin Oncol. 2012 Dec 20;30(36):e373-8. doi: 10.1200/JCO.2012.43.5933. Epub 2012 Nov 13.
    • PARP Inhibitors: Targeting the Right Patients.
    • Azvolinsky A.
    • J Natl Cancer Inst. 2012 Dec 19;104(24):1851-2. doi: 10.1093/jnci/djs514. Epub 2012 Dec 10.
    • Clinicopathological features of homologous recombination-deficient epithelial ovarian cancers: sensitivity to PARP inhibitors, platinum, and survival.
    • Mukhopadhyay A, Plummer ER, Elattar A, Soohoo S, Uzir B, Quinn JE, McCluggage WG, Maxwell P, Aneke H, Curtin NJ, Edmondson RJ.
    • Cancer Res. 2012 Nov 15;72(22):5675-82. doi: 10.1158/0008-5472.CAN-12-0324. Epub 2012 Oct 11.
    • Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer.
    • Abkevich V, Timms KM, Hennessy BT, Potter J, Carey MS, Meyer LA, Smith-McCune K, Broaddus R, Lu KH, Chen J, Tran TV, Williams D, Iliev D, Jammulapati S, Fitzgerald LM, Krivak T, Deloia JA, Gutin A, Mills GB, Lanchbury JS.
    • Br J Cancer. 2012 Nov 6;107(10):1776-82. doi: 10.1038/bjc.2012.451. Epub 2012 Oct 9.
    • BRCA1 epigenetic inactivation predicts sensitivity to platinum-based chemotherapy in breast and ovarian cancer.
    • Stefansson OA, Villanueva A, Vidal A, Martí L, Esteller M.
    • Epigenetics. 2012 Nov;7(11):1225-9. doi: 10.4161/epi.22561. Epub 2012 Oct 15.
    • Evaluation of candidate biomarkers to predict cancer cell sensitivity or resistance to PARP-1 inhibitor treatment.
    • Oplustilova L, Wolanin K, Mistrik M, Korinkova G, Simkova D, Bouchal J, Lenobel R, Bartkova J, Lau A, O'Connor MJ, Lukas J, Bartek J.
    • Cell Cycle. 2012 Oct 15;11(20):3837-50. doi: 10.4161/cc.22026. Epub 2012 Sep 14.

    Related:

    Comment:

    Addicted to PAR? A closer look at PARP inhibitor sensitivity.

    Comment:

    Predicting PARP inhibitor sensitivity and resistance.

    • Olaparib , PARP1 inhibitor in ovarian cancer.
    • Marchetti C, Imperiale L, Gasparri ML, Palaia I, Pignata S, Boni T, Bellati F, Benedetti Panici P.
    • Expert Opin Investig Drugs. 2012 Oct;21(10):1575-84. Epub 2012 Jul 13.
    • Review
    • Molecular-targeted therapies for ovarian cancer: prospects for the future.
    • Sudo T.
    • Int J Clin Oncol. 2012 Oct;17(5):424-9. doi: 10.1007/s10147-012-0461-1. Epub 2012 Aug 23.
    • Review
    • Identification of DNA Repair Pathways That Affect the Survival of Ovarian Cancer Cells Treated with a Poly(ADP-Ribose) Polymerase Inhibitor in a Novel Drug Combination.
    • Huehls AM, Wagner JM, Huntoon CJ, Karnitz LM.
    • Mol Pharmacol. 2012 Oct;82(4):767-76. Epub 2012 Jul 25.
    • Lack of BRCA testing approval creates snag for cancer trials.
    • Azvolinsky A.
    • Nat Med. 2012 Sep 7;18(9):1310. doi: 10.1038/nm0912-1310a.
    • News
    • Poly (ADP-ribose) polymerase inhibitors: on the horizon of tailored and personalized therapies for epithelial ovarian cancer.
    • Ratner ES, Sartorelli AC, Lin ZP.
    • Curr Opin Oncol. 2012 Sep;24(5):564-71. doi: 10.1097/CCO.0b013e3283564230.
    • Identifying and exploiting defects in the Fanconi anemia/BRCA pathway in oncology.
    • Stecklein SR, Jensen RA.
    • Transl Res. 2012 Sep;160(3):178-97. doi: 10.1016/j.trsl.2012.01.022. Epub 2012 Feb 9.
    • Review
    • BRCA1 and HSP90 cooperate in homologous and non-homologous DNA double-strand-break repair and G2/M checkpoint activation.
    • Stecklein SR, Kumaraswamy E, Behbod F, Wang W, Chaguturu V, Harlan-Williams LM, Jensen RA.
    • Proc Natl Acad Sci U S A. 2012 Aug 21;109(34):13650-5. doi: 10.1073/pnas.1203326109. Epub 2012 Aug 6.
    • Cancer treatment according to BRCA1 and BRCA2 mutations.
    • Maxwell KN, Domchek SM.
    • Nat Rev Clin Oncol. 2012 Aug 14;9(9):520-8. doi: 10.1038/nrclinonc.2012.123. Epub 2012 Jul 24.
    • Review
    • Olaparib in platinum-sensitive ovarian cancer.
    • Kaji D, Miura Y, Takano T.
    • N Engl J Med. 2012 Jul 12;367(2):179; author reply 179-80. doi: 10.1056/NEJMc1205423#SA1.
    • Synthetic lethality of PARP inhibition in BRCA-network disrupted tumor cells is associated with interferon pathway activation and enhanced by interferon-γ.
    • Warrener P, Kim S, Williams SM, Biery M, Gordon M, Toniatti C, Cleary MA, Linsley PS, Carleton M.
    • Apoptosis. 2012 Jul;17(7):691-701. doi: 10.1007/s10495-012-0707-4.
    • HO-3867, a STAT3 inhibitor induces apoptosis by inactivation of STAT3 activity in BRCA1-mutated ovarian cancer cells.
    • Tierney BJ, McCann GA, Cohn DE, Eisenhauer E, Sudhakar M, Kuppusamy P, Hideg K, Selvendiran K.
    • Cancer Biol Ther. 2012 Jul;13(9):766-75. doi: 10.4161/cbt.20559.
    • [Poly(ADP-ribose) polymerase (PARP) inhibitors in BRCA1/2 cancer therapy].
    • Kluzek K, Białkowska A, Koczorowska A, Zdzienicka MZ.
    • Postepy Hig Med Dosw (Online). 2012 Jun 15;66:372-84.
    • BRCA1/2 mutations and expression: response to platinum chemotherapy in patients with advanced stage epithelial ovarian cancer.
    • Dann RB, DeLoia JA, Timms KM, Zorn KK, Potter J, Flake DD 2nd, Lanchbury JS, Krivak TC.
    • Gynecol Oncol. 2012 Jun;125(3):677-82. doi: 10.1016/j.ygyno.2012.03.006. Epub 2012 Mar 8.
    • [PARP inhibitors--theoretical basis and clinical application].
    • Dębska S, Kubicka J, Czyżykowski R, Habib M, Potemski P.
    • Postepy Hig Med Dosw (Online). 2012 May 30;66:311-21.
    • Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer.
    • Ledermann J, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, Scott C, Meier W, Shapira-Frommer R, Safra T, Matei D, Macpherson E, Watkins C, Carmichael J, Matulonis U.
    • N Engl J Med. 2012 Apr 12;366(15):1382-92. doi: 10.1056/NEJMoa1105535. Epub 2012 Mar 27.

    Related:

    Comment, Letter:

    Olaparib in platinum-sensitive ovarian cancer.

    • Telomeric allelic imbalance indicates defective DNA repair and sensitivity to DNA-damaging agents.
    • Birkbak NJ, Wang ZC, Kim JY, Eklund AC, Li Q, Tian R, Bowman-Colin C, Li Y, Greene-Colozzi A, Iglehart JD, Tung N, Ryan PD, Garber JE, Silver DP, Szallasi Z, Richardson AL.
    • Cancer Discov. 2012 Apr;2(4):366-75. doi: 10.1158/2159-8290.CD-11-0206. Epub 2012 Mar 22.
    • A phase I study of veliparib in combination with metronomic cyclophosphamide in adults with refractory solid tumors and lymphomas.
    • Kummar S, Ji J, Morgan R, Lenz HJ, Puhalla SL, Belani CP, Gandara DR, Allen D, Kiesel B, Beumer JH, Newman EM, Rubinstein L, Chen A, Zhang Y, Wang L, Kinders RJ, Parchment RE, Tomaszewski JE, Doroshow JH.
    • Clin Cancer Res. 2012 Mar 15;18(6):1726-34. doi: 10.1158/1078-0432.CCR-11-2821. Epub 2012 Feb 3.
    • Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer.
    • Kaye SB, Lubinski J, Matulonis U, Ang JE, Gourley C, Karlan BY, Amnon A, Bell-McGuinn KM, Chen LM, Friedlander M, Safra T, Vergote I, Wickens M, Lowe ES, Carmichael J, Kaufman B.
    • J Clin Oncol. 2012 Feb 1;30(4):372-9. doi: 10.1200/JCO.2011.36.9215. Epub 2011 Dec 27.

    Related:

    Comment, Editorial:

    Comparing poly (ADP-ribose) polymerase inhibitors with standard chemotherapy in BRCA-mutated, recurrent ovarian cancer: lessons learned from a negative trial.

    • Hereditary ovarian cancer: Beyond the usual suspects.
    • Pennington KP, Swisher EM.
    • Gynecol Oncol. 2012 Feb;124(2):347-53. doi: 10.1016/j.ygyno.2011.12.415.
    • Review
    • PARP inhibition in epithelial ovarian cancer: high hopes undergo a reality check.
    • Zorn KK.
    • Oncology (Williston Park). 2012 Feb;26(2):128-36.

    Related:

    Comment:

    The maze of PARP inhibitors in ovarian cancer.

    Comment:

    The circuitous path of PARP inhibitor development in epithelial ovarian cancer.

    • Therapy-related myeloid neoplasms in epithelial ovarian cancer patients carrying BRCA1 mutation: report of two cases.
    • Melichar B, Laco J, Fridrichová P, Simkovič M, Papajík T, Foretová L.
    • Acta Oncol. 2012 Jan;51(1):136-8. Epub 2011 Aug 22.
    • Genomic instability in breast and ovarian cancers: translation into clinical predictive biomarkers.
    • Vollebergh MA, Jonkers J, Linn SC.
    • Cell Mol Life Sci. 2012 Jan;69(2):223-45. doi: 10.1007/s00018-011-0809-0. Epub 2011 Sep 16.
    • Review
    • Advances in the treatment of ovarian cancer: a potential role of antiinflammatory phytochemicals.
    • Chen SS, Michael A, Butler-Manuel SA.
    • Discov Med. 2012 Jan;13(68):7-17.
    • Biologicals in the upfront treatment of ovarian cancer: focus on bevacizumab and poly (adp-ribose) polymerase inhibitors.
    • Roux R, Zweifel M, Rustin GJ.
    • Am Soc Clin Oncol Educ Book. 2012:340-4. doi: 10.14694/EdBook_AM.2012.32.340.
    • The role of PARP inhibitors in the treatment of ovarian carcinomas.
    • Tinker AV, Gelmon K.
    • Curr Pharm Des. 2012;18(25):3770-4.
    • Review